ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0170

Minimal Clinically Important Difference in Myositis Response Criteria

Khushboo Singh1, Sara Faghihi Kashani2, Tissa Bijoy George3, Siamak Moghadam-Kia4, Dana Ascherman5, Rohit Aggarwal6 and Chester Oddis5, 1UPMC McKeesport, Pittsburgh, PA, 2Stanford University, Stanford, CA, 3UPMC McKeesport, Monroeville, PA, 4University of Pittsburgh Medical Center, Pittsburgh, PA, 5University of Pittsburgh, Pittsburgh, PA, 6Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA

Meeting: ACR Convergence 2022

Keywords: Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Muscle Biology, Myositis and Myopathies Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: ACR/EULAR myositis response criteria were developed to assess the patient’s disease activity, response to therapy, and long-term outcome as a standardized measure to be used in clinical and therapeutic trials. The criteria consist of six core set measures which are then combined in a weighted manner to calculate a Total Improvement Score (TIS) to assess minimal, moderate, and major improvement in myositis patients.

Minimal Clinically Important Difference (MCID) of TIS, which is the smallest magnitude of change in a score that is clinically significant for patients and clinicians, has not been evaluated in myositis patients. We aimed to determine the MCID in adult-onset Polymyositis (PM) and Dermatomyositis (DM) patients across two clinical trials and one observational study.

Methods: Adult PM and DM patients from the (Rituximab in Myositis (RIM) trial (N = 148), Tocilizumab in Myositis (TIM) trial (N = 36), and an observational study of physical activity monitors and patient reported outcome (PAMPRO) (N = 50) were included. All six core set measures (extra-muscular, patient and MD global disease activity, MMT, HAQ Disability Index (HAQ-DI), and CK levels) were measured at baseline and 24-weeks, and TIS was assessed at 24-weeks. HAQ-DI as well as physician and patient impression of change were used as anchors to calculate score difference between the two time-points and to determine if they had significant correlation with TIS. The HAQ-DI was categorized into two groups: change in HAQ-DI< 0.22 or ≥ 0.22 based on prior rheumatologic studies of HAQ-DI and change in MCID. Physician impression of change was also categorized into two groups: improved (markedly/moderately/slightly improved) and not-improved (unchanged, slightly/moderately/markedly worse). MCID was calculated by anchor based and distributive methods using effect size and a linear regression model. We calculated the weighted average of MCID of TIS based on physician impression of change and HAQ-DI using the results of the three cohorts.

Results: A total of 216 patients with adult-onset PM and DM were identified for analysis. Patient impression of change did not correlate with TIS, and therefore MCID was not calculated for this anchor. The correlation coefficient between TIS and physician impression of change and HAQ-change of 0.22 across the three different studies are reported in Table 1.

The TIS MCID using HAQ-DI change of 0.22 as the anchor was -21.53, -16.14, -38.64 based on effect size, and 22.14, 12.52, 37.38 based on linear regression in the RIM, TIM and PAMPRO studies, respectively. The TIS MCID using physician impression of change was -22.16, -27.47, -47.75 based on effect size, and 22.44, 27.14, 37.44 based on linear regression in the RIM, TIM and PAMPRO studies, respectively. The weighted average of TIS MCID based on physician impression of change was 26.60 and based on HAQ-DI change of 0.22 was 23.48.

Conclusion: Physician impression of change and HAQ-DI change analysis suggested that the MCID of TIS should be 26.60 and 23.48, respectively. These values are higher than the threshold set by physician consensus (TIS ≥ 20). Other independent and patient outcome-based measures did not contribute to these models.

Supporting image 1

Table 1: Spearman correlation coefficient of physician assessment of change (improved versus not-improved) and HAQ-DI change of 0.22 with TIS

Supporting image 2

Table 2: MCID of TIS across three different cohorts based on physician assessment of change (improved versus not-improved) and HAQ-DI change of 0.22


Disclosures: K. Singh, None; S. Faghihi Kashani, None; T. Bijoy George, None; S. Moghadam-Kia, None; D. Ascherman, None; R. Aggarwal, Mallinckrodt, Bristol Myers Squibb, EMD Serono, Pfizer, Octapharma, CSL Behring, Q32, Kezar, AstraZeneca, Alexion, Argenx, Boehringer Ingelheim, Corbus, Janssen, Kyverna, Roivant, AbbVie, Jubilant, Orphazyme, Genentech; C. Oddis, None.

To cite this abstract in AMA style:

Singh K, Faghihi Kashani S, Bijoy George T, Moghadam-Kia S, Ascherman D, Aggarwal R, Oddis C. Minimal Clinically Important Difference in Myositis Response Criteria [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/minimal-clinically-important-difference-in-myositis-response-criteria/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/minimal-clinically-important-difference-in-myositis-response-criteria/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology